He Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
He Zheng has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Mengyao Liu
Department of Oncology, The Affiliated Shaoyang Hospital City, Hengyang Medical School, University of South China, Shaoyang, Hunan 422000, China
1 shared publicationWen Zeng
Department of Scientific Research and Teaching, The Central Hospital of Shaoyang City, Shaoyang, Hunan 422000, China
1 shared publication- Yong Chen
Department of Oncology, The Central Hospital of Shaoyang City, Shaoyang, Hunan 422000, China
1 shared publication Zilin Chen
Department of Oncology, The Affiliated Shaoyang Hospital City, Hengyang Medical School, University of South China, Shaoyang, Hunan 422000, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2023
- Published by Wiley in European Journal of Cancer Care
- Vol. 2023 (1)
Prognostic Analysis on Different Tumor Sizes for 14634 Hepatocellular Carcinoma Patients
Aim . This study investigated the effect of tumor size and other factors on the survival and prognosis of hepatocellular carcinoma (HCC). Methods . All HCC populations based on the National Cancer Institute’s SEER database to receive from 2010 to 2016 were employed in the study. Results . This study enrolled a total of 14,634 HCC. Among them, 1,686 patients had tumors ≤ 2 cm, 6,169 patients had tumors 2–5 cm, and 6,779 patients had tumors > 5 cm. The results using univariate analysis showed that all factors were significant prognostic factors for overall survival and specific survival. Patients with tumor size ≤ 2 cm were more likely to survive, while patients with tumor size > 5 cm had a lower survival rate. Patients who had surgery or surgery plus chemotherapy had a higher chance of survival in stages I‐II, and the survival rate declined smoothly during the 80 months. The change rate of the mortality rate increased rapidly during the period of 1–12 cm; afterwards, the mortality rate’s HR was basically and smoothly maintained at a high level. Conclusions . Tumor size was positively correlated with the mortality rate of HCC. Survival rates were greater in patients with tumors ≤ 2 cm who underwent surgery or surgery plus chemotherapy. Patients with HCC in the early stage had a higher survival probability particularly when they had experienced surgery or surgery plus chemotherapy.
- 1 January 2023
- Published by Wiley in European Journal of Cancer Care
- Vol. 2023 (1)
Open AccessPrognostic Analysis on Different Tumor Sizes for 14634 Hepatocellular Carcinoma Patients
Aim . This study investigated the effect of tumor size and other factors on the survival and prognosis of hepatocellular carcinoma (HCC). Methods . All HCC populations based on the National Cancer Institute’s SEER database to receive from 2010 to 2016 were employed in the study. Results . This study enrolled a total of 14,634 HCC. Among them, 1,686 patients had tumors ≤ 2 cm, 6,169 patients had tumors 2–5 cm, and 6,779 patients had tumors > 5 cm. The results using univariate analysis showed that all factors were significant prognostic factors for overall survival and specific survival. Patients with tumor size ≤ 2 cm were more likely to survive, while patients with tumor size > 5 cm had a lower survival rate. Patients who had surgery or surgery plus chemotherapy had a higher chance of survival in stages I‐II, and the survival rate declined smoothly during the 80 months. The change rate of the mortality rate increased rapidly during the period of 1–12 cm; afterwards, the mortality rate’s HR was basically and smoothly maintained at a high level. Conclusions . Tumor size was positively correlated with the mortality rate of HCC. Survival rates were greater in patients with tumors ≤ 2 cm who underwent surgery or surgery plus chemotherapy. Patients with HCC in the early stage had a higher survival probability particularly when they had experienced surgery or surgery plus chemotherapy.